Share on PinterestSputnik V shows promise in post-registration trials in Russia.Photo credit: Natalia Kolesnikova/AFP via Getty ImagesFirstly, scientists at the Gamaleya Research Institute of Epidemiology and Microbiology, in Moscow, devised a vaccine that elicits a robust immune response, with no serious side effects in humans. The last few weeks also saw the development of a…
By Michael Le Page , Clare Wilson , Jessica Hamzelou , Adam Vaughan , Conrad Quilty-Harper and Layal Liverpool Sputnik V, Gamaleya National CenterTHE RUSSIAN DIRECT INVESTMENT FUND Latest coronavirus news as of 5 pm on 4 September Russia’s vaccine candidate produced antibody and T-cell responses in early-stage trial A preliminary trial of Russia’s coronavirus…
By Michael Le Page Denis Rebrikov says he will still move forward with gene-editing work to prevent heritable deafnessAndrey Rudakov/Bloomberg via Getty Russian biologist Denis Rebrikov has told New Scientist that he still plans to use CRISPR genome editing to prevent children inheriting deafness, despite a major international report out today saying it isn’t yet…
You don't have permission to access "http://www.medpagetoday.com/podcasts/healthwatch/123146" on this server. Reference #18.d494d817.1790474508.33970988 https://errors.edgesuite.net/18.d494d817.1790474508.33970988
4 min read WHEN YOU FIND something good, it makes sense to capitalize on it, right? James Gunn’s DC Universe is still in its relative infancy, and its earlygoings have been good, but a bit bumpy. Creature Commandos and the second season of Peacemaker were strong and had their audience, and Superman was very good.
